Loading
A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting.
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL is a phase 2 interventional study registered as NCT06500273 by Allogene Therapeutics, with 250 participants planned, started 2024-06-18 and due to reach its primary completion in 2027-12. Interventions recorded: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.
Shares Allogene Therapeutics, Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Allogene Therapeutics, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.